Zystor Therapeutics
Founded Year
2004Stage
Acquired | AcquiredTotal Raised
$8.5MValuation
$0000About Zystor Therapeutics
ZyStor Therapeutics is a biotechnology company developing therapeutics, with the potential to significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases (LSDs).
Missing: Zystor Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Zystor Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Zystor Therapeutics Patents
Zystor Therapeutics has filed 4 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/30/2007 | 12/28/2010 | Rare diseases, Autosomal recessive disorders, Syndromes, Cell biology, Clusters of differentiation | Grant |
Application Date | 5/30/2007 |
|---|---|
Grant Date | 12/28/2010 |
Title | |
Related Topics | Rare diseases, Autosomal recessive disorders, Syndromes, Cell biology, Clusters of differentiation |
Status | Grant |
Zystor Therapeutics Frequently Asked Questions (FAQ)
When was Zystor Therapeutics founded?
Zystor Therapeutics was founded in 2004.
Where is Zystor Therapeutics's headquarters?
Zystor Therapeutics's headquarters is located at 10437 Innovation Drive, Milwaukee.
What is Zystor Therapeutics's latest funding round?
Zystor Therapeutics's latest funding round is Acquired.
How much did Zystor Therapeutics raise?
Zystor Therapeutics raised a total of $8.5M.
Who are the investors of Zystor Therapeutics?
Investors of Zystor Therapeutics include BioMarin Pharmaceutical, Prolog Ventures, Venture Investors, Apjohn Ventures, Mason Wells and 7 more.
Who are Zystor Therapeutics's competitors?
Competitors of Zystor Therapeutics include BaroFold, Raptor Pharmaceutical Corp., Motif BioSciences, Larimar Therapeutics, REGiMMUNE and 12 more.
Compare Zystor Therapeutics to Competitors
Alice Therapeutics is a biotechnology company.
Halsa Pharmaceuticals is a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases.
LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.
ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.